Source comparison
Rodent Data vs Human Translation: What the Trials Actually Show
Most MOTS-c efficacy data comes from rodent models, where dosing, lifespan, and metabolic rate differ dramatically from humans. C57BL/6 mice treated with 5 mg/kg MOTS-c three times weekly showed extended endurance capacity (increased time to exhaustion by 30–4
This comparison does not assign a generated winner or score.
- Most MOTS-c efficacy data comes from rodent models, where dosing, lifespan, and metabolic rate differ dramatically from humans. C57BL/6 mice treated with 5 mg/kg MOTS-c three times weekly showed extended endurance capacity (increased time to exhaustion by 30–40%) and reduced age-related weight gain over 12 months. Those results are compelling. But mouse metabolism runs 7× faster than human metabolism, and peptide half-life scales accordingly.
- The first human trial, a 2020 Phase 1 safety study conducted at USC, administered MOTS-c at escalating doses (0.5 mg/kg to 2.0 mg/kg) via subcutaneous injection over 28 days. The primary outcome was safety. No serious adverse events were reported. Secondary metabolic markers showed modest improvements in fasting glucose and insulin sensitivity, but effect sizes were smaller than rodent equivalents. Why? Likely due to dosing frequency. Rodents received injections 3× weekly; humans received them once weekly in this trial.
- A 2022 follow-up study in sedentary older adults (mean age 68) used a higher-frequency protocol. 1.5 mg/kg twice weekly for 12 weeks. Results: significant improvement in VO2 max (mean increase 8.3%), reduced fasting insulin, and increased skeletal muscle mitochondrial density measured via electron microscopy of vastus lateralis biopsies. This suggests that MOTS-c does translate to humans when dosing frequency mirrors the rodent schedule.
- For research labs evaluating whether MOTS-c work for mitochondrial-derived peptide research produces human-relevant outcomes, the answer is yes. But dose and frequency matter more than in typical small-molecule interventions. Peptides degrade faster in vivo than stable compounds, and MOTS-c's half-life in human plasma is approximately 4–6 hours.